PMID- 25367165
OWN - NLM
STAT- MEDLINE
DCOM- 20151019
LR  - 20220310
IS  - 1941-2010 (Electronic)
IS  - 1935-1232 (Linking)
VI  - 8
IP  - 4
DP  - 2015 Jan
TI  - Switching to iloperidone: An omnibus of clinically relevant observations from a 
      12-week, open-label, randomized clinical trial in 500 persons with schizophrenia.
PG  - 183-95
LID - 10.3371/CSRP.CIWE.103114 [doi]
AB  - OBJECTIVE: To describe secondary analyses from a 12-week, randomized, open-label 
      trial where adult schizophrenia outpatients receiving risperidone, olanzapine, or 
      aripiprazole were switched to iloperidone. METHODS: Patients were randomized into 
      two groups: one where the antecedent antipsychotic dose was titrated downwards to 
      zero over 2 weeks (n=240), and the other group where the antecedent antipsychotic 
      was abruptly stopped (n=260). Adaptations of the Clinical Global Impression scale 
      were used to evaluate clinical changes. Other assessments included the reporting 
      of adverse events (AEs), study discontinuation, body weight, and metabolic 
      variables. RESULTS: Improvement was steady throughout the study for both gradual- 
      and immediate-switch groups starting at Week 1 and continuing through Week 12. 
      Discontinuations due to AEs in the first 2 weeks of treatment were higher for the 
      immediate-switch group compared with the gradual-switch group (10.8% vs. 5.4%, 
      NNT 19, 95% CI 10-151). Fewer patients in the gradual-switch group experienced 
      dizziness as an AE, whereas a higher percentage of patients in the 
      immediate-switch group exhibited earlier onset of a therapeutic response within 
      the first 2 weeks; both groups were comparable thereafter with low rates of 
      dizziness and similar efficacy outcomes. CONCLUSIONS: Switching to iloperidone 
      can be accomplished either with a gradual crossover or immediate discontinuation 
      of the prior antipsychotic; however, the immediate-switch method is associated 
      with greater proportion of initial dizziness. The observed outcomes are 
      consistent with what has been previously reported regarding iloperidone's 
      favorable akathisia/EPS profile and modest impact on somnolence/sedation, body 
      weight, and metabolic variables.
FAU - Citrome, Leslie
AU  - Citrome L
AD  - New York Medical College, Valhalla, NY.
FAU - Weiden, Peter J
AU  - Weiden PJ
AD  - University of Illinois at Chicago, Chicago, IL.
FAU - Alva, Gus
AU  - Alva G
AD  - ATP Clinical Research, Costa Mesa, CA.
FAU - Glick, Ira D
AU  - Glick ID
AD  - University School of Medicine Stanford, Stanford, CA.
FAU - Jackson, Richard
AU  - Jackson R
AD  - Wayne State University, Detroit, MI.
FAU - Mattingly, Greg
AU  - Mattingly G
AD  - Washington University School of Medicine, St. Louis, MO.
FAU - Kianifard, Farid
AU  - Kianifard F
AD  - Novartis Pharmaceuticals Corporation, East Hanover, NJ.
FAU - Meng, Xiangyi
AU  - Meng X
AD  - Novartis Pharmaceuticals Corporation, East Hanover, NJ.
FAU - Winseck, Adam
AU  - Winseck A
AD  - Novartis Pharmaceuticals Corporation, East Hanover, NJ.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Schizophr Relat Psychoses
JT  - Clinical schizophrenia & related psychoses
JID - 101312513
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Isoxazoles)
RN  - 0 (Piperazines)
RN  - 0 (Piperidines)
RN  - 0 (Quinolones)
RN  - 12794-10-4 (Benzodiazepines)
RN  - 82VFR53I78 (Aripiprazole)
RN  - L6UH7ZF8HC (Risperidone)
RN  - N7U69T4SZR (Olanzapine)
RN  - VPO7KJ050N (iloperidone)
SB  - IM
MH  - Adult
MH  - Antipsychotic Agents/adverse effects/*therapeutic use
MH  - Aripiprazole
MH  - Benzodiazepines/administration & dosage
MH  - Dizziness/chemically induced
MH  - Female
MH  - Humans
MH  - Isoxazoles/adverse effects/*therapeutic use
MH  - Male
MH  - Olanzapine
MH  - Piperazines/administration & dosage
MH  - Piperidines/adverse effects/*therapeutic use
MH  - Quinolones/administration & dosage
MH  - Risperidone/administration & dosage
MH  - Schizophrenia/*drug therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Efficacy
OT  - Iloperidone
OT  - Safety
OT  - Schizophrenia
OT  - Switching
OT  - Tolerability
EDAT- 2014/11/05 06:00
MHDA- 2015/10/20 06:00
CRDT- 2014/11/05 06:00
PHST- 2014/11/05 06:00 [entrez]
PHST- 2014/11/05 06:00 [pubmed]
PHST- 2015/10/20 06:00 [medline]
AID - M550025348059081 [pii]
AID - 10.3371/CSRP.CIWE.103114 [doi]
PST - ppublish
SO  - Clin Schizophr Relat Psychoses. 2015 Jan;8(4):183-95. doi: 
      10.3371/CSRP.CIWE.103114.